Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. - Wikidata - awgldk - TriplyDB

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

http://www.wikidata.org/entity/Q42928039

about

Cardiac regulation by phosphoinositide 3-kinases and PTEN Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo Akt1 in endothelial cell and angiogenesis Phosphoinositide 3-kinase: friend and foe in cardiovascular disease Ongoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray?Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs Akt isoforms in vascular disease Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging NADPH oxidases in heart failure: poachers or gamekeepers?Molecular basis of physiological heart growth: fundamental concepts and new players Optimization of cardiac metabolism in heart failure Heart failure with preserved ejection fraction Cardiac matrix: a clue for future therapy Bone marrow support of the heart in pressure overload is lost with aging Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth The cell biology of disease: cellular mechanisms of cardiomyopathy.The role of sirtuins in cardiac disease Molecular Imaging of Angiogenesis in Cardiac Regeneration The critical role of Akt in cardiovascular function MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study)Redox-sensitive Akt and Src regulate coronary collateral growth in metabolic syndrome Phosphorylation of the Twist1-family basic helix-loop-helix transcription factors is involved in pathological cardiac remodeling Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation Regulation of cardiac hypertrophic signaling by prolyl isomerase Pin1 Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis.Cancer drug related cardiotoxicity during breast cancer treatment.Insulin Signaling and Heart Failure.Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart.Increased afterload induces pathological cardiac hypertrophy: a new in vitro model

P2860

Q24317248-D078DF70-A76E-4A8E-945B-A80DD8A5E6EF Q24648140-7BCF745D-64E2-4989-9F56-6995CB65BE56 Q24676614-2DA5F3B6-7BBF-4DC0-9DDD-74E2F1FE74FD Q26796228-B44E7881-CB4C-496D-AEDA-745AB02CC64B Q26800197-8F1B6190-CCBD-4371-B789-5785D4A257D0 Q26827482-C88F4560-245C-45A5-AAA4-25DB70FBF7B0 Q26851565-21FDFD2D-E930-44D5-95CC-20933D7A65AE Q26998765-B28E203B-334A-4C5F-9B20-145AEDD4466C Q27001094-5F4EFFF1-E6C1-4E1C-B250-C96FDE5AD13B Q27006868-2F1B8681-1CDF-4BD5-94E0-A4F89104CFD4 Q27023021-BC711A99-C4A0-4E26-B52B-61F3F079CE09 Q27024008-1EB6F89B-BE98-43BF-ABDA-42F333BEEE21 Q27026864-C3536677-2F82-4AE4-8D44-FF23F54E3556 Q27313372-96876EBC-A716-4DA3-B04F-162B305E9F00 Q27320013-ACA25BFA-94CD-4C69-9E44-CC2BAA181527 Q27686758-1C233536-7B15-4FEB-9C96-E746507DB7E9 Q27693274-EA8D3BEF-374F-4E2F-B396-3F84FE6A98DC Q28073273-EA1C5DD5-08AE-4602-A67A-B1ED7973457D Q28083829-3FBD11D4-46B5-47D6-99DA-2C9F648385C9 Q28115504-65D0D4DE-A71B-4D44-812F-7EC9E7F53858 Q28250153-3B9DC24D-8473-46BB-8578-E7F0D8687EC2 Q28267272-D804A5D8-564F-4A13-8CC1-EBEBEA41D84B Q28291007-8D9D4A95-1550-4FAA-B5F9-61BB1D23920A Q28384869-02D05DCF-0356-4ADF-9BCB-0A1602E0F211 Q28389912-1778114C-404D-48AB-A379-E13BBEF66D2B Q28477980-9B9DB0B2-EC1A-46FA-A187-2231A52E85A7 Q28509556-A27DFE95-5839-4292-A2BC-A8A460626A93 Q28535743-CF1D286E-C8DB-4E03-B7A5-63DF8C91F3EE Q28539225-DDCDB110-5835-48BE-8E0D-D7A5B8308E4C Q28572621-D9960503-D167-4DA6-AD5E-E8EF6EB699C2 Q28575610-AF8B7A31-D1C1-4B94-8773-6C2B8F800462 Q28575727-55207DF6-DFD8-48FF-AF4B-A96666D68B97 Q29871466-B24DE159-4F62-456D-ADD0-6CAFA59363AB Q30251498-777744E6-D307-447D-9E35-71AF847205A0 Q30377910-833EAFD4-F91E-4458-907F-FF6E18DFD6E5 Q30384457-E6EBDA46-B7D4-4021-984B-ECD55BE61357 Q30426853-6CFB3284-20CF-4B7B-9662-00A791FD7D67 Q30477341-F3314B42-DCE4-4040-BFEB-9EDB8E5271D7 Q30487913-CD36D4A5-8133-4039-AF1A-C71348DCA45D Q30528600-4BCACBA0-560B-4946-98D5-226558640476

P2860

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

http://www.wikidata.org/entity/Q42928039

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Disruption of coordinated card ...... e transition to heart failure.

@en

Disruption of coordinated card ...... e transition to heart failure.

@nl

type

label

Disruption of coordinated card ...... e transition to heart failure.

@en

Disruption of coordinated card ...... e transition to heart failure.

@nl

prefLabel

Disruption of coordinated card ...... e transition to heart failure.

@en

Disruption of coordinated card ...... e transition to heart failure.

@nl

P1433

Q42928039-967215FF-6075-474C-BDB7-D3BC98FF3D86

P1476

Q42928039-32DE242C-D210-4F24-8B52-E5B44718BEFC

P2093

Q42928039-175D2F3D-B086-48C7-AFA1-8AB73B591279

Q42928039-5878FA86-086B-46B0-ABA1-AE6187384ADC

Q42928039-9DC80399-95DC-4646-80FC-4E633B40D714

Q42928039-AABCA129-A1E2-4B34-B143-0B1AB5BF63B7

Q42928039-B684404A-07D0-423F-8B27-C0C8D1E45FCA

Q42928039-C1CBB824-C68B-4B80-ABE7-B0A82A8889A2

Q42928039-E89B3C0D-83A8-401C-86F0-079A0E3B7B03

P2860

Q42928039-0EA0C19C-0584-4B9A-8BC9-AE72E33ECE8D

Q42928039-117BA48C-89D9-4E0F-91B5-CDCF90287CE7

Q42928039-1E10BBA9-4566-4F5A-BEAB-C095E11CFA30

Q42928039-1E21E382-0821-4B6B-9401-D5AA0B880907

Q42928039-1FDB3F07-E9A2-410E-BA36-6C675C256C05

Q42928039-201252E1-D14D-4542-8A92-1BCB62029B03

Q42928039-23B4F752-D58D-4074-962B-0DB131871175

Q42928039-2846AADA-09F6-4B12-92A8-31EAC22C838E

Q42928039-29B297E1-4B87-4577-880B-4738D75688EA

Q42928039-419EA8BB-6E19-4C78-93F8-AEA5454277D8

P304

Q42928039-34CB43E7-3439-4194-B62B-D83C8AFE6FD5

P31

Q42928039-67686A63-40FF-45BE-AF7E-250C28B9A3F8

P356

Q42928039-B99E225D-C776-4486-9838-E0FCBCAE38FA

P407

Q42928039-EA58AA85-DF85-46A9-80F1-3860AB944052

P433

Q42928039-608CE9EE-9245-4EE7-9762-6963D990B9DE

P478

Q42928039-B65EED31-4BBE-4EA8-9C1A-83B7D5F3A272

P50

Q42928039-575872DE-E686-433B-9BA5-97BD2FAF716C

P577

Q42928039-64D5BD8D-E6E3-42F2-894D-F9163D4C7ECA

P698

Q42928039-0DEC9635-9B71-4653-AC57-6EDD8DE1B7D1

P921

Q42928039-909C024B-0AF4-4E21-A0DE-680548ECD1F1

P932

Q42928039-E4032203-44EA-410F-BBB2-80E387B79EBD

P356

P1433

Journal of Clinical Investigation

P1476

Disruption of coordinated card ...... e transition to heart failure.

@en

P2093

Ichiro Shiojima

http://www.w3.org/2001/XMLSchema#string

Kaori Sato

http://www.w3.org/2001/XMLSchema#string

Masahiro Ito

http://www.w3.org/2001/XMLSchema#string

Ronglih Liao

http://www.w3.org/2001/XMLSchema#string

Stephan Schiekofer

http://www.w3.org/2001/XMLSchema#string

Wilson S Colucci

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Izumiya

http://www.w3.org/2001/XMLSchema#string

P2860

Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta

Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development

Vascular-specific growth factors and blood vessel formation

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

Cardiac hypertrophy: the good, the bad, and the ugly

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

P304

2108-2118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI24682

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16075055

http://www.w3.org/2001/XMLSchema#string

P921

P932

1180541

http://www.w3.org/2001/XMLSchema#string